RxDoctor Payments Data

Heather Rowe, MD

Psychiatry · Virginia Beach, VANPI 1235172016

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 360 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 26.8% of the total. Reporting peaked in 2019 at $5,253 and has fallen 81.6% since, to $966 in 2025. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,943in general payments, 2019–2025

Across 360 payments — averaging $27.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$3K
  • AbbVie$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Johnson & Johnson$1K
  • Alkermes, Inc.$599
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$9,83599%
  • Education$1081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,943 in reported general payments places this provider in the 90th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$45,097
Medicare patients
109
Services billed
2,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine89$613,009
Invega SustennaPaliperidone Palmitate201$568,142
IngrezzaValbenazine Tosylate58$457,451
AristadaAripiprazole Lauroxil85$215,494
Abilify MaintenaAripiprazole86$205,604
Invega TrinzaPaliperidone Palmitate23$184,997
CaplytaLumateperone Tosylate67$139,373
VraylarCariprazine Hcl75$137,675
TrintellixVortioxetine Hydrobromide78$68,317
RexultiBrexpiprazole29$47,631
Lurasidone Hcl192$40,373
Clozapine312$28,578
Aripiprazole138$19,028
FanaptIloperidone14$16,331
Haloperidol Decanoate252$11,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$1,003$753,139224 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,010$613,00989 claims
Neurocrine Biosciences, Inc.Ingrezza$260$457,45158 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$402$253,235115 claims
Alkermes, Inc.Aristada$599$215,49485 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$70$139,37367 claims
AbbVieVraylar$1,260$137,67575 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall$163$75,75290 claims
Vanda Pharmaceuticals Inc.Fanapt$147$16,33114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →